The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio
Goldman Sachs, RTX and Abbott lead Zacks' latest research, with growth drivers balanced by costs, supply-chain and market risks.
Zacks
More News
Top Research Reports for Goldman Sachs, RTX & Abbott
Goldman Sachs, RTX and Abbott headline today's research, with growth drivers, risks and strategic moves shaping their outlooks.
Zacks
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in.
Zacks
Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong
PRPO's second-quarter 2026 revenue momentum strengthens on higher diagnostic volumes and record product sales, alongside positive adjusted EBITDA and cash generation.
Zacks
PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?
Precipio and NeoGenomics take different approaches to cancer diagnostics, but which oncology stock looks more compelling now? Let's dive in.
Zacks
The Zacks Analyst Blog Highlights Caterpillar, Palo Alto Networks, Toyota Motor and Precipio
Caterpillar, Palo Alto Networks and Toyota headline new research as analysts weigh growth drivers, demand trends and risks across key industries.
Zacks
Top Analyst Reports for Caterpillar, Palo Alto & Toyota
Caterpillar, Palo Alto Networks and Toyota headline Zacks' top analyst reports, highlighting growth drivers, opportunities and key risks shaping outlooks.